Inovalon Holdings, Inc. (NASDAQ:INOV) CFO Jonathan R. Boldt sold 2,500 shares of the stock in a transaction on Tuesday, November 17th. The shares were sold at an average price of $18.24, for a total value of $45,600.00. Following the sale, the chief financial officer now owns 239,190 shares of the company’s stock, valued at approximately $4,362,825.60. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

NASDAQ INOV opened at $18.79 on Friday. Inovalon Holdings, Inc. has a 1-year low of $13.39 and a 1-year high of $27.93. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 1.33. The company has a market capitalization of $2.92 billion, a PE ratio of 469.87, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76. The firm’s fifty day simple moving average is $23.49 and its 200-day simple moving average is $21.84.

Inovalon (NASDAQ:INOV) last posted its quarterly earnings results on Wednesday, October 28th. The technology company reported $0.16 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.12 by $0.04. The business had revenue of $161.38 million for the quarter, compared to the consensus estimate of $179.27 million. Inovalon had a net margin of 0.87% and a return on equity of 9.07%. As a group, analysts predict that Inovalon Holdings, Inc. will post 0.45 EPS for the current year.

Several analysts have issued reports on INOV shares. SVB Leerink boosted their target price on shares of Inovalon from $21.00 to $25.00 and gave the company an “outperform” rating in a research note on Thursday, July 30th. KeyCorp boosted their target price on shares of Inovalon from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Thursday, September 3rd. Zacks Investment Research downgraded shares of Inovalon from a “buy” rating to a “hold” rating in a research note on Wednesday, July 29th. Morgan Stanley boosted their target price on shares of Inovalon from $18.00 to $25.00 and gave the company an “equal weight” rating in a research note on Friday, July 31st. Finally, Citigroup boosted their target price on shares of Inovalon from $24.00 to $26.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and four have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $23.44.

A number of institutional investors have recently bought and sold shares of INOV. Redwood Investments LLC acquired a new position in Inovalon during the second quarter worth $19,245,000. Bernzott Capital Advisors increased its position in Inovalon by 27.1% during the third quarter. Bernzott Capital Advisors now owns 2,061,327 shares of the technology company’s stock worth $54,522,000 after buying an additional 439,550 shares during the last quarter. Spence Asset Management acquired a new position in Inovalon during the third quarter worth $9,969,000. Castleark Management LLC acquired a new position in Inovalon during the third quarter worth $9,702,000. Finally, Nordea Investment Management AB increased its position in Inovalon by 99.9% during the second quarter. Nordea Investment Management AB now owns 618,572 shares of the technology company’s stock worth $11,480,000 after buying an additional 309,120 shares during the last quarter. 33.44% of the stock is currently owned by hedge funds and other institutional investors.

Inovalon Company Profile

Inovalon Holdings, Inc provides cloud-based platforms for data-driven healthcare. It operates Inovalon ONE Platform, a cloud-based platform that interconnect with the healthcare ecosystem to aggregate and analyze data in real-time, as well as empowers the application in resulting insights. The company also operates myABILITY software platform, an integrated set of cloud-based applications for providers that offers connectivity, administrative, clinical and quality analysis, management, and performance improvement capabilities to acute, post-acute, and ambulatory point-of-care provider facilities.

See Also: Gap Down Stocks

Insider Buying and Selling by Quarter for Inovalon (NASDAQ:INOV)

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with MarketBeat.com's FREE daily email newsletter.